MetaVia (NASDAQ:MTVA – Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect MetaVia to post earnings of ($0.72) per share for the quarter.
MetaVia Price Performance
Shares of MetaVia stock opened at $1.59 on Thursday. The stock has a 50-day simple moving average of $1.72. MetaVia has a 1 year low of $1.29 and a 1 year high of $5.30.
Analysts Set New Price Targets
Separately, HC Wainwright began coverage on shares of MetaVia in a research note on Monday, December 30th. They issued a “buy” rating and a $12.00 price target for the company.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than MetaVia
- Quiet Period Expirations Explained
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Differences Between Momentum Investing and Long Term Investing
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Insider Buying Explained: What Investors Need to Know
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
